Firms cash in on GSK JV with Novartis

May 2014

Partners at Linklaters and Freshfields Bruckhaus Deringer are among the 500 lawyers to have cashed in on the billion-dollar joint venture between Novartis and GlaxoSmithKline (GSK), The Lawyer reported. The pharmaceutical giants will swap assets as part of the deal, with GSK acquiring Novartis’ global vaccines unit, excluding its flu division, for USD7.1bn. Novartis will take on GSK’s cancer drugs...

To continue reading this article, Existing users can sign in / subscribe / renew and new users are requested to register.

May 2024

TO GC Talk Series #51 - Bad Leavers: Whistleblowing, corporate espionage & misappropriations

22 May 2024

A breakfast seminar for in-house counsel | In association with HAS Law Firm and Legal Research Partner LexisNexis

8.30am - 10.30am

At Dubai, UAE

ICCA Congress 2024 Hong Kong - ‘International Arbitration: A Human Endeavour’

05 - 08 May 2024

ICCA's biennial Congresses attract a large number of participants from across the globe and have made significant contributions to the development of dispute resolution theory and practice. Renowned for stimulating in-depth discussion and providing new insights on matters related to international arbitration, the ICCA Congress is the largest regular conference devoted to international arbitration and caters to both practitioners looking to build a practice in international arbitration and experts in the arbitration community.

	Cover Story
	POWERING THE FUTURE
	An analysis of the EU approach to the more sustainable eFuel sector.
	Digital Version

Firms cash in on GSK JV with Novartis

Previous Editions